AstraZeneca (AZN) has agreed to acquire EsoBiotec for a total consideration of up to $1 billion, EsoBiotec said Monday.
The consideration consists of an initial payment of $425 million, and up to $575 million in contingency payments.
The deal includes EsoBiotec's Engineered NanoBody Lentiviral delivery platform which has potential application in cancer therapy, the biotechnology company said.
Closing of the deal is expected to occur in Q2, subject to customary closing conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。